icrf 193 has been researched along with Leukemia in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ando, J; Ando, M; Isobe, Y; Oshimi, K; Sasaki, M; Sugimoto, K; Suto, H; Tamayose, K; Tsutsui, M | 1 |
1 other study(ies) available for icrf 193 and Leukemia
Article | Year |
---|---|
Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1.
Topics: Antibiotics, Antineoplastic; Benzoquinones; Cell Death; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Diketopiperazines; DNA Damage; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; G2 Phase; Genes, p53; HeLa Cells; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Jurkat Cells; Lactams, Macrocyclic; Leukemia; Piperazines; Protein Kinases | 2008 |